U.S. District Court Denies Roche Motion to Dismiss Amgen Patent Infringement Lawsuit
Court Will Proceed on the Merits of Amgen's Claim That Roche's peg-EPO Infringes Amgen's EPO Patents
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Oct. 20, 2006--Amgen
(NASDAQ:AMGN) announced that a U.S. Federal District Court in Boston
today denied Roche's motion to dismiss Amgen's patent infringement
lawsuit against Roche. The court today also denied a motion by Ortho
Biotech to intervene as a co-plaintiff in the case.
"The judicial process can now move forward towards resolution of
the substantive issue of patent infringement and we look forward to
addressing the merits of this case," said David Scott, Amgen's senior
vice president, general counsel and secretary.
Amgen continues to believe that Roche's peg-EPO product violates
Amgen's patents and does not provide any clinical or patient benefit
over Amgen's innovative therapies, EPOGEN(R) (Epoetin alfa) and
Aranesp(R) (darbepoetin alfa).
Amgen revolutionized anemia treatment with the introduction of
EPOGEN. EPOGEN, along with Aranesp, represent over four million
combined patient-years of experience. Amgen has continued to invest
heavily in research to improve the lives of patients with kidney,
cancer and cardiovascular disease.
Amgen discovers, develops and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the
first companies to realize the new science's promise by bringing safe
and effective medicines from lab, to manufacturing plant, to patient.
Amgen therapeutics have changed the practice of medicine, helping
millions of people around the world in the fight against cancer,
kidney disease, rheumatoid arthritis, and other serious illnesses.
With a broad and deep pipeline of potential new medicines, Amgen
remains committed to advancing science to dramatically improve
people's lives. To learn more about our pioneering science and our
vital medicines, visit www.amgen.com.
EDITOR'S NOTE: An electronic version of this news release may be
accessed via our Web site at www.amgen.com. Journalists and media
representatives may sign up to receive all news releases
electronically at time of announcement by filling out a short form in
the Media section of the Web site.
CONTACT: Amgen, Thousand Oaks
Marie Fay, 805-447-0081 (media)
Arvind Sood, 805-447-1060 (investors)